

GROWTH HORMONE

# Tesamorelin

Stabilised GHRH Analogue

FDA-approved GHRH analogue for visceral fat reduction. Strong GH-pulse amplification.

**MECHANISM**

Stabilised GHRH analogue — enhanced pituitary GH pulse amplitude

**DOSAGE**

1–2 mg once daily SC

**HALF-LIFE**

~26 minutes (sustained GH elevation)

**FORMAT**

Lyophilised powder

**BATCH**

NU-TES-1573

**LOT**

676573

**CAS**

218949-48-5

**FORMULA**

C221H366N72O...

**ISSUED**

2025-07-04

**RETEST**

2026-07-04

## OVERVIEW

Tesamorelin is a stabilised GHRH analogue with greater potency and a longer half-life than native GHRH. It is the only GHRH-class peptide with FDA approval (Egrifta) — specifically for HIV-associated lipodystrophy, where it reduces visceral adipose tissue by ~15–18%.

## MECHANISM OF ACTION

Stabilised GHRH analogue — enhanced pituitary GH pulse amplitude

## KEY RESEARCH BENEFITS

- FDA-approved mechanism for visceral fat reduction
- Reduces trunk fat by 15–18% in clinical studies
- Stronger GH pulse amplitude than sermorelin
- Improves cognitive function in older adults
- Insulin-sensitising secondary effects

## RESEARCH NOTES

Pivotal FDA trials (LIPO-010A/B, N = 816) showed significant visceral fat reduction and IGF-1 normalisation. Cognitive benefits reported in a separate MCI trial (NCT01699867).

## STORAGE & STABILITY

Lyophilised: -20 °C, stable >=24 months. Reconstituted: 2–8 °C, use within 21 days.